DA VINCI study: Change in approach to cholesterol management will be needed to reduce the implementation gap between guidelines and clinical practice in Europe
Author:
- 1 December 2020
- journal article
- editorial
- Published by Elsevier in Atherosclerosis
- Vol. 314, 74-76
Abstract
No abstract availableKeywords
Funding Information
- EAS
This publication has 7 references indexed in Scilit:
- Risk for Recurrent Cardiovascular Events and Expected Risk Reduction With Optimal Treatment 1 Year After an Acute Coronary SyndromeThe American Journal of Cardiology, 2020
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskEuropean Heart Journal, 2019
- Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countriesAtherosclerosis, 2019
- Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeNew England Journal of Medicine, 2018
- Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes MellitusCirculation, 2018
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine, 2017
- 2016 ESC/EAS Guidelines for the Management of DyslipidaemiasEuropean Heart Journal, 2016